A detailed history of Ashford Capital Management Inc transactions in Incyte Corp stock. As of the latest transaction made, Ashford Capital Management Inc holds 240,640 shares of INCY stock, worth $16.6 Million. This represents 2.17% of its overall portfolio holdings.

Number of Shares
240,640
Previous 244,770 1.69%
Holding current value
$16.6 Million
Previous $14.8 Million 7.2%
% of portfolio
2.17%
Previous 2.2%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$57.33 - $68.61 $236,772 - $283,359
-4,130 Reduced 1.69%
240,640 $15.9 Million
Q2 2024

Aug 15, 2024

SELL
$51.18 - $63.75 $5.33 Million - $6.63 Million
-104,075 Reduced 29.83%
244,770 $14.8 Million
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $1.35 Million - $1.59 Million
-23,924 Reduced 6.42%
348,845 $19.9 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $3.97 Million - $4.88 Million
-76,075 Reduced 16.95%
372,769 $23.4 Million
Q3 2023

Nov 15, 2023

SELL
$57.77 - $65.93 $576,544 - $657,981
-9,980 Reduced 2.18%
448,844 $25.9 Million
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $193,394 - $239,593
3,173 Added 0.7%
458,824 $28.6 Million
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $253,038 - $309,894
3,603 Added 0.8%
455,651 $32.9 Million
Q4 2022

Feb 15, 2023

BUY
$67.18 - $84.11 $1.28 Million - $1.61 Million
19,110 Added 4.41%
452,048 $36.3 Million
Q3 2022

Nov 15, 2022

SELL
$66.18 - $82.86 $1.26 Million - $1.58 Million
-19,023 Reduced 4.21%
432,938 $28.9 Million
Q2 2022

Aug 15, 2022

BUY
$66.18 - $83.18 $233,085 - $292,959
3,522 Added 0.79%
451,961 $34.3 Million
Q1 2022

May 16, 2022

BUY
$66.02 - $79.71 $1.32 Million - $1.59 Million
19,924 Added 4.65%
448,439 $35.6 Million
Q4 2021

Feb 15, 2022

BUY
$63.34 - $74.11 $5.64 Million - $6.59 Million
88,970 Added 26.2%
428,515 $31.5 Million
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $422,663 - $517,143
6,155 Added 1.85%
339,545 $23.4 Million
Q2 2021

Aug 26, 2021

SELL
$79.87 - $87.53 $164,132 - $179,874
-2,055 Reduced 0.61%
333,390 $28 Million
Q1 2021

May 14, 2021

BUY
$76.02 - $100.5 $109,164 - $144,318
1,436 Added 0.43%
335,445 $27.3 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $7.6 Million - $9.2 Million
94,139 Added 39.25%
334,009 $29.1 Million
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $520,117 - $670,644
-6,114 Reduced 2.49%
239,870 $21.5 Million
Q2 2020

Aug 17, 2020

SELL
$74.18 - $108.93 $2.36 Million - $3.46 Million
-31,805 Reduced 11.45%
245,984 $25.6 Million
Q1 2020

May 15, 2020

BUY
$63.18 - $85.97 $6.94 Million - $9.44 Million
109,813 Added 65.37%
277,789 $20.3 Million
Q4 2019

Feb 14, 2020

BUY
$73.04 - $95.72 $1.12 Million - $1.47 Million
15,353 Added 10.06%
167,976 $14.7 Million
Q3 2019

Nov 15, 2019

BUY
$72.82 - $86.52 $95,030 - $112,908
1,305 Added 0.86%
152,623 $11.3 Million
Q2 2019

Aug 15, 2019

SELL
$73.52 - $88.7 $115,426 - $139,259
-1,570 Reduced 1.03%
151,318 $12.9 Million
Q1 2019

May 15, 2019

BUY
$63.56 - $88.17 $2.26 Million - $3.14 Million
35,586 Added 30.34%
152,888 $13.2 Million
Q4 2018

Feb 15, 2019

SELL
$58.5 - $69.94 $3.15 Million - $3.77 Million
-53,853 Reduced 31.46%
117,302 $7.46 Million
Q3 2018

Nov 15, 2018

BUY
$61.75 - $74.23 $946,318 - $1.14 Million
15,325 Added 9.83%
171,155 $11.8 Million
Q2 2018

Aug 15, 2018

BUY
$60.85 - $83.98 $763,241 - $1.05 Million
12,543 Added 8.75%
155,830 $10.4 Million
Q1 2018

May 15, 2018

BUY
$83.06 - $100.98 $3.65 Million - $4.44 Million
43,969 Added 44.27%
143,287 $11.9 Million
Q4 2017

Feb 15, 2018

SELL
$93.56 - $116.6 $158,116 - $197,054
-1,690 Reduced 1.67%
99,318 $9.41 Million
Q3 2017

Nov 15, 2017

SELL
$109.15 - $138.27 $101,400 - $128,452
-929 Reduced 0.91%
101,008 $11.8 Million
Q2 2017

Aug 21, 2017

BUY
N/A
101,937
101,937 $12.8 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Ashford Capital Management Inc Portfolio

Follow Ashford Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ashford Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ashford Capital Management Inc with notifications on news.